These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 18281547)

  • 1. A phase I and pharmacokinetic trial of erlotinib in combination with weekly docetaxel in patients with taxane-naive malignancies.
    Chiorean EG; Porter JM; Foster AE; Al Omari AS; Yoder CA; Fife KL; Strother RM; Murry DJ; Yu M; Jones DR; Sweeney CJ
    Clin Cancer Res; 2008 Feb; 14(4):1131-7. PubMed ID: 18281547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancer.
    LoRusso PM; Jones SF; Koch KM; Arya N; Fleming RA; Loftiss J; Pandite L; Gadgeel S; Weber BL; Burris HA
    J Clin Oncol; 2008 Jun; 26(18):3051-6. PubMed ID: 18565892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase-I dose escalation and sequencing study of docetaxel and continuous infusion topotecan in patients with advanced malignancies.
    Posey JA; Wang H; Hamilton J; Delgrosso A; Zhang R; Freda T; Zamboni WC
    Cancer Chemother Pharmacol; 2005 Aug; 56(2):182-8. PubMed ID: 15838660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors.
    Messersmith WA; Baker SD; Lassiter L; Sullivan RA; Dinh K; Almuete VI; Wright JJ; Donehower RC; Carducci MA; Armstrong DK
    Clin Cancer Res; 2006 Feb; 12(4):1270-5. PubMed ID: 16489083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An European Organisation for Research and Treatment of Cancer phase I study of lapatinib and docetaxel as neoadjuvant treatment for human epidermal growth factor receptor 2 (HER2) positive locally-advanced/inflammatory or large operable breast cancer.
    Bonnefoi H; Zaman K; Debled M; Fiche M; Fournier M; Nobahar M; Pierga JY; Koch KM; Bartlett J; Zimmer A; Marreaud S; Bogaerts J; Cameron D
    Eur J Cancer; 2013 Jan; 49(2):281-9. PubMed ID: 22999386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I and pharmacokinetic study of weekly docetaxel, cisplatin, and daily capecitabine in patients with advanced solid tumors.
    Fakih MG; Creaven PJ; Ramnath N; Trump D; Javle M; Strychor S; Repinski TV; Zamboni BA; Schwarz JK; French RA; Zamboni WC
    Clin Cancer Res; 2005 Aug; 11(16):5942-9. PubMed ID: 16115937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors.
    Fury MG; Solit DB; Su YB; Rosen N; Sirotnak FM; Smith RP; Azzoli CG; Gomez JE; Miller VA; Kris MG; Pizzo BA; Henry R; Pfister DG; Rizvi NA
    Cancer Chemother Pharmacol; 2007 Mar; 59(4):467-75. PubMed ID: 16896930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarker-based phase I dose-escalation, pharmacokinetic, and pharmacodynamic study of oral apricoxib in combination with erlotinib in advanced nonsmall cell lung cancer.
    Reckamp K; Gitlitz B; Chen LC; Patel R; Milne G; Syto M; Jezior D; Zaknoen S
    Cancer; 2011 Feb; 117(4):809-18. PubMed ID: 20922800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequence effect of docetaxel and carboplatin on toxicity, tumor response and pharmacokinetics in non-small-cell lung cancer patients: a phase I study of two sequences.
    Ando M; Saka H; Ando Y; Minami H; Kuzuya T; Yamamoto M; Watanabe A; Sakai S; Shimokata K; Hasegawa Y
    Cancer Chemother Pharmacol; 2005 Jun; 55(6):552-8. PubMed ID: 15856233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Docetaxel, ifosfamide and cisplatin in solid tumour treatment: a phase I study.
    Specenier P; Rasschaert M; Van den Brande J; Dyck J; Schrijvers D; Huizing MT; Vermorken JB
    Anticancer Drugs; 2010 Mar; 21(3):306-12. PubMed ID: 20087171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I and pharmacokinetic study of docetaxel administered in combination with continuous intravenous infusion of 5-fluorouracil in patients with advanced solid tumors.
    Van Den Neste E; de Valeriola D; Kerger J; Bleiberg H; Kusenda Z; Brassinne C; Bartholomeus S; Selleslags J; Hennebert P; Wythouck H; Cazenave I; Lefresne-Soulas F; Piccart M
    Clin Cancer Res; 2000 Jan; 6(1):64-71. PubMed ID: 10656433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I and pharmacokinetic study of erlotinib (OSI-774) in combination with docetaxel in squamous cell carcinoma of the head and neck (SSCHN).
    Kraut EH; Rhoades C; Zhang Y; Cheng H; Aimiumu J; Chen P; Lang J; Young DC; Agrawal A; Dancey J; Chan KK; Grever MR
    Cancer Chemother Pharmacol; 2011 Mar; 67(3):579-86. PubMed ID: 20490801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of bi-weekly docetaxel for recurrent or advanced gastric cancer patients whose disease progressed by prior chemotherapy.
    Kimura Y; Yano H; Taniguchi H; Iwazawa T; Danno K; Kagara N; Kanoh T; Ohnishi T; Tono T; Nakano Y; Monden T; Imaoka S
    Jpn J Clin Oncol; 2011 Jun; 41(6):747-51. PubMed ID: 21498408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer.
    Kotsakis A; Agelaki S; Vardakis N; Stathopoulos G; Vamvakas L; Kalykaki A; Kentepozidis N; Kontopodis E; Sfakiotaki G; Mavroudis D; Georgoulias V
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):415-22. PubMed ID: 21069335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase I trial of weekly docetaxel and topotecan for solid tumors.
    Lim WT; Baggstrom MQ; Read W; Fracasso PM; Govindan R
    Acta Oncol; 2008; 47(2):311-5. PubMed ID: 17896192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: a dose-escalation study.
    Twelves C; Trigo JM; Jones R; De Rosa F; Rakhit A; Fettner S; Wright T; Baselga J
    Eur J Cancer; 2008 Feb; 44(3):419-26. PubMed ID: 18249110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer.
    Mathew P; Thall PF; Jones D; Perez C; Bucana C; Troncoso P; Kim SJ; Fidler IJ; Logothetis C
    J Clin Oncol; 2004 Aug; 22(16):3323-9. PubMed ID: 15310776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer.
    Sym SJ; Ryu MH; Kang HJ; Lee SS; Chang HM; Lee JL; Kim TW; Yook JH; Oh ST; Kim BS; Kang YK
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):373-80. PubMed ID: 19936751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A dose escalation study of docetaxel plus capecitabine in combination with oxaliplatin in patients with advanced solid tumors.
    Amarantidis K; Xenidis N; Chelis L; Chiotis A; Tentes A; Chatzaki E; Kortsaris A; Polychronidis A; Karakitsos P; Kakolyris S
    Acta Oncol; 2010; 49(2):245-51. PubMed ID: 19839918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics.
    Morgan RJ; Doroshow JH; Synold T; Lim D; Shibata S; Margolin K; Schwarz R; Leong L; Somlo G; Twardowski P; Yen Y; Chow W; Lin P; Paz B; Chu D; Frankel P; Stalter S
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5896-901. PubMed ID: 14676112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.